About this trial
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.
Eligibility criteria
Qualifiers
Females aged ≥18 years
HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension
BMI ≥25 kg/m2 prior to pregnancy or in the first trimester
Requirement for antihypertensive medication within one week of delivery
Disqualifiers
LV ejection fraction <50% or history of clinical heart failure with reduced or preserved ejection fraction
Hypertrophic or other genetic cardiomyopathy
Hyperkalemia: potassium >5.3 mEq/L
BMI at screening ≥50 kg/m2
Trial design
Treatments tested in this trial
- spironolactone 25 mg orally once daily
- Placebo tablet to match spironolactone
Treatment groups
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Brigham and Women's Hospital
Collaborator
University of Pittsburgh Medical Center
Collaborator